新2会员网址(www.hg108.vip):Pharmaniaga to ride on high demand for its products
MIDF Research said the group has increased its profitability in the last few months as demand for pharmaceutical products continued to rise well into the second half of the year.新2会员网址(www.hg108.vip)实时更新发布最新最快最有效的新2网址和新2最新网址,包括新2手机网址,新2备用网址,皇冠最新网址,新2足球网址,新2网址大全。
KUALA LUMPUR: Pharmaniaga Bhd is expected to post positive earnings in financial years 2022 (FY22) and FY23 as demand for pharmaceutical products continues to increase.
In a note, MIDF Research said the group has increased its profitability in the last few months as demand for pharmaceutical products continued to rise well into the second half of the year.
“Despite having no problems with raw materials, Pharmaniaga has stated that the high demand has caused manufacturing to go beyond 100% capacity, and paracetamol production had increased to more than twice the normal capacity.
“Liquid drugs are also facing a demand and supply imbalance, as such, Pharmaniaga’s Indonesian plants have been requested to deliver the syrups,” the research house pointed out.
,,皇冠体育信用(www.hg9988.vip)是一个开放皇冠网址即时比分、皇冠网址代理最新登录线路、皇冠网址会员最新登录线路、皇冠网址代理APP下载、皇冠网址会员APP下载、皇冠网址线路APP下载、皇冠网址电脑版下载、皇冠网址手机版下载、皇冠体育信用官方平台。
MIDF Research also added that Pharmaniaga’s logistics segment will be renewing its concession agreement with the government in the fourth quarter of 2022, assuring a steady order of drugs for public hospitals in the near term.
Additionally, the group’s efforts to push its brands to become household names could reset the public sentiment that only certain brands of drugs would give out the same effect, hence boosting its future income.
“We are also optimistic on its vending machine venture which is part of the pharmaceutical sector’s solution to accessibility and digital healthcare,” it said. — Bernama
转载说明:本文转载自Sunbet。
网友评论
usdt无需实名买入卖出(www.usdt8.vip)
回复轻赞一下
足球免费推荐(www.hgbbs.vip)
回复环球ug代理开户(www.ugbet.us)
回复五星好评(o^^o)
三寸季光丶不忘卿°
回复老夫心动了怎么办
欧博开户(www.aLLbetgame.vip)
回复USDT不用实名交易(www.usdt8.vip)
回复贸易畅通是指,各国合作解决投资贸易便利化问题,消除贸易和投资壁垒,降低贸易投资成本,建构区域内的良好营商环境。从2013年至2021年,中国与沿线国家年度贸易额从1.04万亿美元扩大到1.8万亿美元,增长了73%。中国对沿线国家直接投资累计达1,613亿美元,而沿线国家在华实际累计投资712亿美元。中国在沿线国家承包工程新签合同额累计约1.08万亿美元,涵盖交通、电力等多个领域。中国与沿线国家进出口总值从占外贸总值比重的25%提升到29.7%。中国企业在沿线国家建设的境外经贸合作园区累计投资430.8亿美元,为当地创造了34.6万个就业岗位。氪金我都愿意
手机新2管理端(www.hg108.vip)
回复内容不错,继续加油。